Treatment of Infiltrative Basal Cell Carcinomas by inhibiting the Fibroblast Growth Factor (FGF)-Signal Transducer and Activator of Transcription (STAT)-3 Signalling Pathways
- *Corresponding Author:
- Dr. Pedro Cuevas
Servicio de Histología
Departamento de Investigación
IRYCIS, Hospital Universitario Ramón y Cajal
Ctra. de Colmenar,km. 9.100, E2034-Madrid-Spain
E-mail: [email protected]
Received Date: September 23, 2011; Accepted Date: November 05, 2011; Published Date: November 07, 2011
Citation: Cuevas P, Angulo J, Cuevas-Bourdier A, Salgüero I, Giménez-Gallego G (2011) Treatment of Infiltrative Basal Cell Carcinomas by inhibiting the Fibroblast Growth Factor (FGF)-Signal Transducer and Activator of Transcription (STAT)-3 Signalling Pathways. J Cancer Sci Ther S3:003. doi:10.4172/1948-5956.S3-003
Copyright: © 2011 Cuevas P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Over-expression of FGF/STAT-3 signalling pathways or aberrant regulation of their activities has been implicated in many forms of human malignancies, including skin neoplasms. Therefore, targeting FGF/STAT-3 signalling pathways represents an attractive strategy for development of basal cell carcinoma (BCC) treatment by simultaneously inhibiting tumor cell growth and survival, and also tumor angiogenesis. Here, we describe the efficacy of a safe, potent and selective FGF inhibitor –dobesilate- in BCC patients. Anti-tumor effect of dobesilate correlates with promotion of apoptosis, and inhibition of both cell proliferation and angiogenesis. Our data support dobesilate as an agent for chemoprevention and therapy of skin cancers by inhibiting FGF/STAT-3 oncogenic signalling axis.